flavopereirine: a beta-carboline alkaloid; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 65171 |
| CHEMBL ID | 463736 |
| MeSH ID | M0105712 |
| Synonym |
|---|
| flavopereirine |
| 3-ethyl-12h-indolo[2,3-a]quinolizin-5-ium |
| CHEMBL463736 |
| pb 100 |
| 12h-indolo(2,3-a)quinolizin-5-ium, 3-ethyl- |
| 6784-38-9 |
| DTXSID80218080 |
| AKOS040751809 |
| flavopereirine perchlorate(p) |
| PD127732 |
Flavopereirine is a β-carboline alkaloid that has antiplasmodial activity. Its antiproliferative effect in different cancers remains unclear.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Flavopereirine is a β-carboline alkaloid that has antiplasmodial activity, and its antiproliferative effect in different cancers remains unclear." | ( Flavopereirine induces cell cycle arrest and apoptosis via the AKT/p38 MAPK/ERK1/2 signaling pathway in human breast cancer cells. Chen, MS; Lee, YR; Li, YZ; Lin, WC; Sheu, SM; Tsai, YS; Tseng, YS; Yeh, HT, 2019) | 2.68 |
Flavopereirine has anti-proliferation ability in cancer cells. Whether it regulates autophagy in breast cancer cells remains unclear.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Flavopereirine has anti-proliferation ability in cancer cells, but whether it regulates autophagy in breast cancer cells remains unclear." | ( Flavopereirine Inhibits Autophagy via the AKT/p38 MAPK Signaling Pathway in MDA-MB-231 Cells. Chen, MS; Lee, YR; Li, YZ; Lin, WC; Sheu, SM; Tseng, YS; Yeh, HT, 2020) | 2.72 |
| "Flavopereirine has been identified to be a potential anti-cancer agent in several types of human cancer. " | ( Flavopereirine Suppresses the Progression of Human Oral Cancer by Inhibiting the JAK-STAT Signaling Pathway via Targeting LASP1. Huang, J; Wu, Z; Xu, J, 2021) | 3.51 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (11.11) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 4 (44.44) | 24.3611 |
| 2020's | 2 (22.22) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (26.18) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 10 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||